Abstract
Objective
This nationwide population-based cohort study evaluated the association between acute kidney injury (AKI) and transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).
Methods
The case cohort included patients with HCC who had undergone TACE treatment between 1 January 1998 and 31 March 2010. Patients with baseline chronic kidney disease, with baseline end-stage renal disease, and aged younger than 20 years were excluded. HCC patients with TACE and HCC patients without TACE were matched 1:1 in terms of propensity scores.
Results
A total of 1132 HCC patients with TACE and 1132 HCC patients without TACE (controls) were enrolled, of which 72 and 66 patients developed AKI, respectively. After adjustment for age, sex, comorbidity, and other medications, the risk of AKI was higher in HCC patients with TACE [hazard ratio (HR) = 1.66, 95% CI = 1.17–2.34]. The HRs of post-TACE AKI were 1.56 (95% CI = 1.02–2.37) and 1.74 (95% CI = 1.23–2.48) for patients having at least one comorbidity and less frequent sessions of TACE (≤3 times), respectively.
Conclusions
Our study demonstrates that TACE increases the risk of AKI in patients with HCC without chronic kidney disease or end-stage renal disease.
Key points
• Seventy-two of1132 patients with TACE and 62/1132 patients without TACE developed AKI.
• AKI risk was higher in HCC patients with TACE.
• HRs were 1.56 and 1.74 for those with comorbidities and less frequent TACE.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750
Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491
Poon RT, Fan ST, Tsang FH, Wong J (2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235:466–486
Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524
Bismuth H, Morino M, Sherlock D et al (1992) Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 163:387–394
Stefanini GF, Amorati P, Biselli M et al (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. an Italian experience. Cancer 75:2427–2434
Nakoa N, Kamino K, Miura K et al (1991) Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization. AJR Am J Roentgenol 156:1177–1179
Huang YH, Chen CH, Chang TT et al (2004) The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int 24:419–424
Aspelin P, Aubry P, Fransson SG et al (2003) Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491–499
Barrett BJ, Parfrey PS (2006) Clinical practice. preventing nephropathy induced by contrast medium. N Engl J Med 354:379–386
Choi H, Kim Y, Kim SM et al (2012) Intravenous albumin for the prevention of contrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease undergoing contrast-enhanced CT. Kidney Res Clin Pract 31:106–111
Huo TI, Wu JC, Huang YH et al (2004) Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 19:999–1007
Hsu CY, Huang YH, Su CW et al (2010) Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 30:77–84
Huo TI, Wu JC, Lee PC, Chang FY, Lee SD (2004) Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 24:210–215
Zhou C, Wang R, Ding Y et al (2014) Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma. Int J Clin Exp Pathol 7:2579–2586
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20:236–242
Parsons L (2001) Performing a 1: N case–control match on propensity score. SUGI 29
Persson PB, Hansell P, Liss P (2005) Pathophysiology of contrast medium-induced nephropathy. Kidney Int 68:14–22
Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7:1713–1721
Uchino S, Kellum JA, Bellomo R et al (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813–818
Wald R, Quinn RR, Luo J et al (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302:1179–1185
Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81:442–448
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B (2009) Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 15:1459–1464
Moreau R, Lebrec D (2003) Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 37:233–243
Chang FC, Lirng JF, Luo CB et al (2008) Patients with head and neck cancers and associated postirradiated carotid blowout syndrome: endovascular therapeutic methods and outcomes. J Vasc Surg 47:936–945
Hayakawa K, Tanikake M, Kirishima T et al (2014) The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). Eur Radiol 24:1105–1111
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52
Vogl TJ, Lammer J, Lencioni R et al (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197:W562–W570
Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004787.pub2:CD004787
Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264
Waikar SS, Wald R, Chertow GM et al (2006) Validity of International classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 17:1688–1694
Lameire N (2014) Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 7:11–22
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Prof. Chia-Hung Kao.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Funding
This study is supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan, and Health and Welfare Surcharge of Tobacco Products, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003, Taiwan). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Ethical approval
This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC2-115-CR1).
Informed consent
Written informed consent was waived by the Institutional Review Board.
Methodology
• retrospective
• observational study
• performed in the national-wide population-based database
Rights and permissions
About this article
Cite this article
Lee, BC., Liu, KL., Lin, CL. et al. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study. Eur Radiol 27, 4482–4489 (2017). https://doi.org/10.1007/s00330-017-4893-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-017-4893-x